KLRS Company Profile and Key Details

KLRS has shown sold momentum, gaining 10.97% over the past week and 111.88% over the past quarter, though year-to-date performance is up 16.23%. Short-term trend indicators are bearishly aligned (SMA20 10.81%, SMA50 12.87%, SMA200 96.23%). The stock’s 14-day RSI is 57.28 (neutral), while the ATR of 0.97 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.14% below its high and over 393.46% above its low. Average 10-day trading volume of 97.01 thousand shares is significantly above the 3-month average of 62.67 thousand, indicating heightened recent market interest.

Kalaris Therapeutics Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.33. This means the shares are trading below this model’s fair value.

Kalaris Therapeutics Inc generated EPS of -$7.40 over the past year. Five-year average earnings growth is -6.86%. Wall Street analysts project EPS growth of 48.05% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $14.00. The high target offers 295.19% upside. The low target suggests 140.55% downside. The mean target is $19.00. This offers 226.46% upside. Kalaris Therapeutics Inc earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -3.03%. The prior quarter beat by 19.61%. Over the last six quarters, Apple has recorded several small beats. These include -71.43% in November 12, 2024.

Kalaris Therapeutics Inc (NASDAQ:KLRS) closed at $5.87 USD, gaining $0.05 (0.86%) from the previous close of $5.82. The stock is currently mid-range between its 52-week high and low $2.14 and $11.88. With a market capitalization of about $109.78 million, Kalaris Therapeutics Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~0.18). Key stats such as the average daily volume over the past year has been around 64.06 thousand shares, trading with heavier-than-usual volume. Headquartered in Cambridge, MA, Kalaris Therapeutics Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrew Oxtoby, the company employs approximately 14 people and listed since July 30, 2020. Kalaris Therapeutics Inc operates as a pharmaceutical company.

Kalaris Therapeutics Inc has 18.70 million shares outstanding. The public float is 4.31 million shares, elevated short interest at 2.34% of float. This equals 110.79 thousand shares. The short ratio is 2.22 days. Institutional investors hold 83.39% of the float. Insiders own 16.17%. Over the past six months, insider transactions show balanced activity. They sold 1.92 thousand shares across 1 transactions.

Kalaris Therapeutics Inc (NASDAQ:KLRS) shares are up 16.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kalaris Therapeutics Inc trading at a premium to the broader market with a P/E of -3.05. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $19.00, suggesting 226.46% upside. Our AI forecast model points to short-term weakness (-25.95% over two weeks), a medium-term fall (-63.92% over three months), and a longer-term gain (617.87% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Kalaris Therapeutics Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.95%, with price expected at $4.31 by April 28, 2026, within a range of $3.33 to $5.18 3-Month Outlook: Projected fall of -63.92%, reaching $2.10 by July 13, 2026, with a range of $1.88 to $2.32. 1-Year Outlook: Projected gain of 617.87%, with price at $41.78 by April 14, 2027, within a range of $41.74 to $42.16.

Kalaris Therapeutics Inc trades at a P/E ratio of -3.05, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.68 suggesting the stock is closer to book value. The P/FCF stands at -2.51, also below market averages.